{"title":"多发性硬化症患者的神经束蛋白155、186和140抗体：一项前瞻性先导探索性研究","authors":"Thomas Mathew, Surabhi Garg, Pritam Majumdar, Shagun Bhardwaj, Sudheeran Kannoth, Annamma Mathai, Sumithra Selvam, Molly George, Uday Murgod, Vikram Kamath, Subhash Kaul, Sindhu V Nambiar, Akshata Huddar, Sonia Shivde, Sagar Badachi, Raghunandan Nadig, Sharath Gg Kumar, Sai Kanth Deepalam, Grk Sarma","doi":"10.4103/neurol-india.Neurol-India-D-25-00046","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antineurofascin antibodies (ANFA) have been identified in central and peripheral demyelinating disorders. We present the results of pan-ANFA assay targeting neurofascin (NF) 155, 186, and 140, in a cohort of Indian Multiple Sclerosis (MS) patients.</p><p><strong>Objective: </strong>To assess the presence of antineurofascin antibodies (ANFA) 155, 186, and 140 in patients with MS.</p><p><strong>Methodology: </strong>In this multicenter prospective study, we investigated the presence of antibodies targeting NF155, NF186, and NF140 in Indian MS patients satisfying McDonald's 2017 criteria. ANFA was measured by competitive ELISA technique using human neurofascins.</p><p><strong>Results: </strong>During the 11-month period from November 1, 2023, to September 30, 2024, we tested 71 MS patients for ANFA. Of the 71 MS patients, 57 (80.28%) tested positive for at least one antineurofascin antibody and 15 (21.13%) were positive for two antibodies. Isolated ANFA140 was present in 26 (36.62%) patients, isolated ANFA186 in 13 (18.31%), and isolated ANFA155 in 3 (4.23%). Combined ANFA 186/140 was present in 14 (19.72%) patients and combined ANFA 155/140 in 1 (1.41%).</p><p><strong>Conclusion: </strong>Antibodies to at least one of the neurofascin antigens were present in a significant number of Indian MS patients. ANFA to NF140 and NF186 was found to be more prevalent compared with ANFA against NF155. Further immunological and molecular investigations are required to confirm whether these antibodies are truly pathogenic, disease-modifying, or incidental.</p>","PeriodicalId":19429,"journal":{"name":"Neurology India","volume":"73 3","pages":"533-537"},"PeriodicalIF":0.9000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Neurofascin 155, 186 and 140 Antibodies in Patients with Multiple Sclerosis: A Pilot Prospective Exploratory Study.\",\"authors\":\"Thomas Mathew, Surabhi Garg, Pritam Majumdar, Shagun Bhardwaj, Sudheeran Kannoth, Annamma Mathai, Sumithra Selvam, Molly George, Uday Murgod, Vikram Kamath, Subhash Kaul, Sindhu V Nambiar, Akshata Huddar, Sonia Shivde, Sagar Badachi, Raghunandan Nadig, Sharath Gg Kumar, Sai Kanth Deepalam, Grk Sarma\",\"doi\":\"10.4103/neurol-india.Neurol-India-D-25-00046\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Antineurofascin antibodies (ANFA) have been identified in central and peripheral demyelinating disorders. We present the results of pan-ANFA assay targeting neurofascin (NF) 155, 186, and 140, in a cohort of Indian Multiple Sclerosis (MS) patients.</p><p><strong>Objective: </strong>To assess the presence of antineurofascin antibodies (ANFA) 155, 186, and 140 in patients with MS.</p><p><strong>Methodology: </strong>In this multicenter prospective study, we investigated the presence of antibodies targeting NF155, NF186, and NF140 in Indian MS patients satisfying McDonald's 2017 criteria. ANFA was measured by competitive ELISA technique using human neurofascins.</p><p><strong>Results: </strong>During the 11-month period from November 1, 2023, to September 30, 2024, we tested 71 MS patients for ANFA. Of the 71 MS patients, 57 (80.28%) tested positive for at least one antineurofascin antibody and 15 (21.13%) were positive for two antibodies. Isolated ANFA140 was present in 26 (36.62%) patients, isolated ANFA186 in 13 (18.31%), and isolated ANFA155 in 3 (4.23%). Combined ANFA 186/140 was present in 14 (19.72%) patients and combined ANFA 155/140 in 1 (1.41%).</p><p><strong>Conclusion: </strong>Antibodies to at least one of the neurofascin antigens were present in a significant number of Indian MS patients. ANFA to NF140 and NF186 was found to be more prevalent compared with ANFA against NF155. Further immunological and molecular investigations are required to confirm whether these antibodies are truly pathogenic, disease-modifying, or incidental.</p>\",\"PeriodicalId\":19429,\"journal\":{\"name\":\"Neurology India\",\"volume\":\"73 3\",\"pages\":\"533-537\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Neurology India\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4103/neurol-india.Neurol-India-D-25-00046\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/5/23 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"NEUROSCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neurology India","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4103/neurol-india.Neurol-India-D-25-00046","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/5/23 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"NEUROSCIENCES","Score":null,"Total":0}
Neurofascin 155, 186 and 140 Antibodies in Patients with Multiple Sclerosis: A Pilot Prospective Exploratory Study.
Background: Antineurofascin antibodies (ANFA) have been identified in central and peripheral demyelinating disorders. We present the results of pan-ANFA assay targeting neurofascin (NF) 155, 186, and 140, in a cohort of Indian Multiple Sclerosis (MS) patients.
Objective: To assess the presence of antineurofascin antibodies (ANFA) 155, 186, and 140 in patients with MS.
Methodology: In this multicenter prospective study, we investigated the presence of antibodies targeting NF155, NF186, and NF140 in Indian MS patients satisfying McDonald's 2017 criteria. ANFA was measured by competitive ELISA technique using human neurofascins.
Results: During the 11-month period from November 1, 2023, to September 30, 2024, we tested 71 MS patients for ANFA. Of the 71 MS patients, 57 (80.28%) tested positive for at least one antineurofascin antibody and 15 (21.13%) were positive for two antibodies. Isolated ANFA140 was present in 26 (36.62%) patients, isolated ANFA186 in 13 (18.31%), and isolated ANFA155 in 3 (4.23%). Combined ANFA 186/140 was present in 14 (19.72%) patients and combined ANFA 155/140 in 1 (1.41%).
Conclusion: Antibodies to at least one of the neurofascin antigens were present in a significant number of Indian MS patients. ANFA to NF140 and NF186 was found to be more prevalent compared with ANFA against NF155. Further immunological and molecular investigations are required to confirm whether these antibodies are truly pathogenic, disease-modifying, or incidental.
期刊介绍：
Neurology India (ISSN 0028-3886) is Bi-monthly publication of Neurological Society of India. Neurology India, the show window of the progress of Neurological Sciences in India, has successfully completed 50 years of publication in the year 2002. ‘Neurology India’, along with the Neurological Society of India, has grown stronger with the passing of every year. The full articles of the journal are now available on internet with more than 20000 visitors in a month and the journal is indexed in MEDLINE and Index Medicus, Current Contents, Neuroscience Citation Index and EMBASE in addition to 10 other indexing avenues.
This specialty journal reaches to about 2000 neurologists, neurosurgeons, neuro-psychiatrists, and others working in the fields of neurology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
